Establishing Evidence Based Indication of AN69-oXiris and PMX-HP Blood Purification Therapies Based on the Endotoxin Activity Assay in Septic Patients

The Catholic University of Korea, Seoul St. Mary's Hospital0 个研究点目标入组 50 人开始时间: 2026年7月27日最近更新: 2026年8月3日

适应症

试验速览

暂无简介。

•? Adult patients aged 18 years or older
•? Patients diagnosed with sepsis or septic shock caused by an intra-abdominal infection, such as peritonitis, according to the Sepsis-3 criteria
•? Patients who have undergone emergency surgery for source control and in whom surgical source control has been successfully completed
•? Patients admitted to the Surgical Intensive Care Unit (SICU) for postoperative intensive care
•? Patients in whom endotoxin activity (EA) can be measured using the Endotoxin Activity Assay (EAA)
•? Patients determined by an intensivist to require extracorporeal blood purification therapy with either AN69-oXiris or PMX-HP
•? Patients in whom central venous access can be established and extracorporeal blood purification therapy can be performed
•? Patients who, or whose legally authorized representatives, have received sufficient information about the study and voluntarily provided written informed consent

•? Pediatric patients under 18 years of age
•? Patients in whom surgical source control is incomplete or has not been performed
•? Pregnant or breastfeeding women
•? Patients who refuse to participate in the study or for whom consent from a legally authorized representative cannot be obtained
•? Patients concurrently participating in another clinical study

发起方